Systemic Treatment Containing Temozolomide: The State of the Art and How to Optimize Results Andrew S. Chi, MD, PhD Assistant Professor of Neurology Temozolomide (TMZ) Optimization Overview • Temozolomide is an effective drug in glioblastoma (GBM) • Key for optimization may be in selecting the right patients • Selection using MGMT methylation • Efficacy of dose-dense (dose intense) temozolomide • Combination with anti-angiogenic agents Perry et al, JCO 2010 Temozolomide in Newly Diagnosed Glioblastoma Oral alkylating agent Alkylates (methylates) N-7 or O-6 of guanine Alkylation results in DNA crosslinking, cell death Synergistic cytotoxicity with radiation Guanine • IFRT with concurrent temozolomide at 75 mg/m2/day • Post-radiation: 150-200 mg/m2 for 5/28 days x 6 cycles Stupp et al. NEJM (2005) Temozolomide Improves Survival in Glioblastoma (GBM) EORTC-NCIC Phase III Survival: 14.6 vs 12 months 10% alive at 5 years Stupp et al. Lancet Oncol (2009) Cycles of Post-Chemoradiation Temozolomide? Comparison of 4 randomized trials of newly diagnosed GBM Cycles of TMZ Median OS (months) 6 14.6 RTOG 0525 (control) (2013) 6 - 12 (13%) 16.6 RTOG 0525 (dose dense TMZ) (2013) 6 - 12 (13%) 14.9 RTOG 0825 (control) (2014) 6 - 12 (20%) 16.1 RTOG 0825 (bevacizumab) (2014) 6 - 12 (20%) 15.7 Avaglio (control) (2014) 6 16.7 Avaglio (bevacizumab) (2014) 6 16.8 Trial (year published) EORTC-NCIC (2005) MGMT Promoter DNA Methylation • MGMT: O6-methylguanine–DNA methyltransferase • Rapidly reverses alkylation at the O6 position of guanine • Causes resistance to DNA alkylating agents • MGMT promoter DNA methylation • Prevents transcription of the MGMT protein • Cells cannot repair alkylation of O6-methylguanine • MGMT methylation may therefore sensitize tumors to alkylating therapy • 30-50% of glioblastomas are MGMT methylated MGMT Methylation and Chemosensitivity Esteller et al. N Engl J Med (2000) MGMT Methylation is Prognostic in GBM EORTC-NCIC Median OS MGMT methylated: 21.7 mos MGMT un-methylated: 12.7 mos Hegi et al. N Engl J Med 2005 RTOG 0525 Phase III (dose dense TMZ) Median OS MGMT methylated: 21.2 mos MGMT un-methylated: 14.0 mos Gilbert et al. JCO 2013 MGMT methylation may be predictive EORTC-NCIC MGMT Methylated MGMT Unmethylated Hegi et al. N Engl J Med (2005) Temozolomide for MGMT un-methylated GBM? Median OS (months) Trial EORTC-NCIC RT only (all patients) 12.0 EORTC-NCIC MGMT un-methylated 12.7 RTOG 0525 MGMT un-methylated 14.0 RTOG 0825 (bevacizumab) MGMT un-methylated 14.3 • Should MGMT un-methylated GBM patients receive RT alone? • Clinical trials in newly diagnosed MGMT un-methylated GBM: • RT alone vs. RT + trial agent? MGMT inhibition or depletion • MGMT inhibitors may be combined with alkylating agents • O6- benzylguanine (O6-BG) is a potent MGMT-inactivating agent • O6-BG lowers MGMT levels in normal cells, increasing toxicity from chemotherapy • Phase II trial of O6-BG + BCNU in recurrent malignant glioma (Quinn et al, JCO 2002) • • 66% grade 3/4 thrombocytopenia and neutropenia • No responses, a few stable disease in 18 patients Novel MGMT inhibitors with greater tumor specificity in preclinical evaluation Tolcher et al. Br J Cancer 2003 MGMT depletion MGMT removes methylating/alkylating lesions at the O6 position of guanine by covalently linking methyl/alkyl groups to an internal cysteine present within the MGMT protein - “suicide substrate” Hegi et al. JCO 2008 “Dose-Dense” Temozolomide (ddTMZ) Prolonged exposure to temozolomide can deplete intracellular MGMT in peripheral blood mononuclear cells 7 on / 7 off Tolcher et al. Br J Cancer 2003 21 / 28 days “Dose-Dense” Temozolomide (ddTMZ) Protracted, low-dose (dose-dense) schedules of temozolomide may reduce MGMT levels and exhaust activity Hegi et al. JCO 2008 Phase II trials of ddTMZ in GBM Hegi et al. JCO 2008 • Numerous small, single institution uncontrolled studies • Different tumors in various studies (new GBM, recurrent GBM, grades) • Apparent responses (up to 25%), suggestion of prolonged PFS • Some studies found correlation with MGMT status, some did not ddTMZ in the Maintenance Phase of New GBM RTOG 0525 Phase III trial ddTMZ: 21 / 28 days at 100 mg/m2 Gilbert et al, JCO 2013 Maintenance ddTMZ Did Not Improve Survival RTOG 0525 Phase III trial ddTMZ vs standard TMZ Gilbert et al, JCO 2013 MGMT status was irrelevant for maintenace ddTMZ RTOG 0525 Phase III trial MGMT methylated patients MGMT un-methylated patients Gilbert et al, JCO 2013 ddTMZ in Recurrent GBM - RESCUE Trial 50 mg/m2 daily for 1 year Large, multicenter, phase II, prospective stratification • Group A: Anaplastic glioma with progression after treatment with TMZ on a 5/28 regimen. • Group B1 (early): GBM with progression before completion of 6 cycles of adjuvant TMZ. • Group B2 (extended): GBM with progression while receiving adjuvant TMZ beyond the standard 6 cycles but before completion of adjuvant treatment. • Group B3 (rechallenge): GBM with progression after completion of adjuvant treatment and a treatment-free interval of greater than 2 months. Perry et al, JCO 2010 ddTMZ in Recurrent GBM - RESCUE Trial 50 mg/m2 daily - GBM arms Perry et al, JCO 2010 ddTMZ in Recurrent GBM - RESCUE Trial 50 mg/m2 daily - GBM arms Responses (%) mPFS (months) PFS6 (%) B1 (Early) n = 33 3 3.6 27.3 B2 (Extended) n = 27 0 1.8 7.4 B3 (Rechallenge) n = 28 11 3.7 35.7 GBM Arm Overall 23.9 Reasons for differences in efficacy are unknown Perry et al, JCO 2010 ddTMZ in Recurrent GBM - RESCUE Trial 50 mg/m2 daily - GBM arms mPFS (months) PFS6 (%) Methylated 3.8 40.0 Unmethylated 2.9 36.4 MGMT status • MGMT status determined in archival tissue • Significance of MGMT status at recurrence is unknown • Unclear why MGMT status did not impact prognosis - MGMT depletion? Perry et al, JCO 2010 TMZ in combination with antiangiogenic agents? Vascular Normalization Hypothesis Antiangiogenic agents can “normalize” the abnormal tumor vasculature, and may result in more efficient delivery of drugs and oxygen to the targeted cancer cell Jain R. Science 2005 Bevacizumab + TMZ in Newly Diagnosed GBM Two Randomized, double-blind, placebo-controlled Phase III trials Standard therapy +/- bevacizumab • RTOG 0825 (Gilbert et al NEJM 2014) • • Avaglio (Chinot et al NEJM 2014) • • 978 patients registered 921 patients assigned Co-primary endpoints for both trials: OS and PFS Bevacizumab + TMZ in Newly Diagnosed GBM • OS not different in either trial • RTOG 0825: 15.7 vs 16.1 months • Avaglio: 16.7 vs 16.8 months • PFS increased with bevacizumab in both trials* • RTOG 0825: 10.7 vs 7.3 months* *HR (0.79) and P value (.007) did not meet pre-defined criteria (p=.004) • Avaglio: 10.6 vs 6.2 months (P=.001) Bevacizumab + TMZ in Newly Diagnosed GBM RTOG 0825 PFS OS Avaglio Bevacizumab + TMZ in Recurrent gliomas • Controlled data not available • EORTC 26091 (TAVAREC) randomized trial for recurrent grade II/III glioma • TMZ (standard dosing) vs. TMZ + Bevacizumab TMZ Alone is Effective in Elderly MG 2 recent randomized trials comparing RT vs. TMZ in elderly patients with malignant glioma (MG) • Nordic (Malmstrom et al, Lancel Oncol 2012) • • 60 Gy vs 34 Gy vs standard TMZ x 6 cycles NOA-08 (Wick et al, Lancet Oncol 2012) • 60 Gy vs dose dense TMZ x 6 cycles • TMZ was similar to RT in efficacy • MGMT methylation appeared to predict TMZ efficacy TMZ alone in Elderly GBM Nordic NOA-08 MGMT Methylated MGMT Methylated Malmstrom et al, Lancel Oncol 2012 Conclusions, and where do we go from here? • Optimal use of TMZ - selection of patients who will benefit • MGMT methylated patients benefit • TMZ alone is reasonable for elderly MGMT methylated patients • RT alone is reasonable in all MGMT un-methylated GBM patients • ddTMZ does not seem to improve efficacy in newly diagnosed GBM, regardless of MGMT status • Rationale exists for combination with anti-angiogenic agents, however no clear survival benefit in newly diagnosed GBM. • Recurrent GBM setting: • ddTMZ may have a role, however larger/controlled trials are needed • TMZ + antiangiogenic agents remain to be evaluated
© Copyright 2024